Open AccessBREAST CANCER IN YOUNG PATIENTS. PECULIARITIES OF PROGNOSIS AND ADIUVANT HORMONE THERAPY (A LITERATURE REVIEW)
Author(s) -
Dmitry Kravchenko,
A. Parokonnaya,
M. I. Nechushkin,
Е. А. Никитина,
N D Hakurinova
Publication year - 2017
Publication title -
kliničeskaâ praktika
Language(s) - English
Resource type - Journals
eISSN - 2618-8627
pISSN - 2220-3095
DOI - 10.17816/clinpract8466-75
Subject(s) - medicine , tamoxifen , breast cancer , oncology , disease , amenorrhea , aromatase , hormone therapy , chemotherapy , adjuvant therapy , adjuvant , randomized controlled trial , cancer , hormonal therapy , gynecology , pregnancy , biology , genetics
Breast cancer (BC) keeps being the most predominant malignant disease in women. In recent years, a trend towards “rejuvenescence” of the disease has been observed that affects its features. Despite modern methods of diagnosis and complex treatment used in young patients, survival in this age group are inferior that's associated with biological and morphological peculiarities of BC in young age. Gradually collected data demonstrates that age might be an independent factor exacerbating prognosis. For BC patients younger 40 years, various aspects of hormone therapy remain ambiguous: prolonged tamoxifen use, aromatase inhibitors prescription, ovarian function suppression, a role of chemotherapy-induced amenorrhea on prognosis of young BC patients. The issue of appropriate, personalized adjuvant hormone therapy of BC is complex and heterogenous that requires a necessity to further international randomized trials.